As of November 2013 there have been 31,741 reported adverse reactions to the HPV vaccine, and the position of the Pharmaceutical companies which make the vaccine, as well as the Department of Health and Human Services which holds patents and profits on the vaccine, is that they are all a coincidence.
Call your Congressman and tell them you want an investigation into the HPV vaccine and the damage it is causing to young men and women. Share this video with everyone you know far and wide!
The Canary Party would like to send out a heartfelt Thank you to Alexis, Alisa, Britt, Brooke, Emily, Lisa, Sharon, Karen, Kristie, Dollie, Roxie and Sara for participating in this film and educating the public. We wish all of you answers, help and action. We hope that in some small way our video will garner the support of the public to help raise your voices to a level that will not only be heard but addresses in an impactful way.
“Not a Coincidence” is a campaign started by The Canary Party to address the medical community’s repeated excuse that the symptoms, too many experience, after vaccination are just coincidental. Seizures, fainting, rashes, allergies, GI dysfunction, loss of speech, etc, etc all labeled a coincidence. It’s time to end the excuses and start to listen to the injured and the parents of the injured. They deserve a forum to be heard, they deserve a voice, respect, attention, hearings and answers. They need a medical discovery process that uses their symptoms and their progression of illness in the process of finding treatments. All injured are worthy of being treated individually instead of disregarding their many medical maladies because of a vaccination program that is not allowed to be questioned. It’s time for the government, the medical community and the media to start taking into account the too many that are affected. Please take the time to hear from these beautiful, well-spoken girls and Moms tell their stories of injury after Gardasil.
For more information, go to https://canaryparty.org
Producer: Allison Chapman
Production Services provided by http://Article-Weekly.com
HPV Vaccine VAERS Reports as of November 2013
Total Disabled 981
Did Not Recover 6,248
Abnormal Pap Smear 542
Cervical Dysplasia 221
Cervical Cancer 67
Life Threatening 581
Emergency Room 10,849
Extended Hospital Stay 239
Adverse Events 31,741
HPV Vaccine Studies
Detection of human papillomavir us (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil®
Medical practitioners in nine countries submitted samples of Gardasil® (Merck & Co.) to be tested for the presence of human papillomavirus (HPV) DNA because they suspected that residual recombinant HPV DNA left in the vaccine might have been a contributing factor leading to some of the unexplained post-vaccination side effects. A total of 16 packages of Gardasil® were received from Australia, Bulgaria, France, India, New Zealand, Poland, Russia, Spain and the United States. A nested polymerase chain reaction (PCR) method using the MY09/MY11 degenerate primers for initial amplification and the GP5/GP6-based nested PCR primers for the second amplification were used to prepare the template for direct automated cycle DNA sequencing of a hypervariable segment of the HPV L1 gene which is used for manufacturing of the HPV L1 capsid protein by a DNA recombinant technology in vaccine production. Detection of HPV DNA and HPV genotyping of all positive samples were finally validated by BLAST (Basic Local Alignment Search Tool) analysis of a 45–60 bases sequence of the computer-generated electropherogram. The results showed that all 16 Gardasil® samples, each with a different lot number, contained fragments of HPV-11 DNA, or HPV-18 DNA, or a DNA fragment mixture from both genotypes. The detected HPV DNA was found to be firmly bound to the insoluble, proteinase-resistant fraction, presumably of amorphous aluminum hydroxyphosphate sulfate (AAHS) nanoparticles used as adjuvant. The clinical significance of these residual HPV DNA fragments bound to a particulate mineral-based adjuvant is uncertain after intramuscular injection, and requires further investigation for vaccination safety.
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants.
Colafrancesco S, et al. Show all
Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y.
Am J Reprod Immunol. 2013 Oct;70(4):309-16. doi: 10.1111/aji.12151. Epub 2013 Jul 31.
Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Tel-Hashomer, Israel; Rheumatology Unit, Department of Internal Medicine and Medical Specialities, Sapienza University of Rome, Rome, Italy.
PROBLEM: Post-vaccination autoimmune phenomena are a major facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and different vaccines, including HPV, have been identified as possible causes.
METHOD OF STUDY: The medical history of three young women who presented with secondary amenorrhea following HPV vaccination was collected. Data regarding type of vaccine, number of vaccination, personal, clinical and serological features, as well as response to treatments were analyzed.
RESULTS: All three patients developed secondary amenorrhea following HPV vaccinations, which did not resolve upon treatment with hormone replacement therapies. In all three cases sexual development was normal and genetic screen revealed no pertinent abnormalities (i.e., Turner’s syndrome, Fragile X test were all negative). Serological evaluations showed low levels of estradiol and increased FSH and LH and in two cases, specific auto-antibodies were detected (antiovarian and anti thyroid), suggesting that the HPV vaccine triggered an autoimmune response. Pelvic ultrasound did not reveal any abnormalities in any of the three cases. All three patients experienced a range of common non-specific post-vaccine symptoms including nausea, headache, sleep disturbances, arthralgia and a range of cognitive and psychiatric disturbances. According to these clinical features, a diagnosis of primary ovarian failure (POF) was determined which also fulfilled the required criteria for the ASIA syndrome.
CONCLUSION: We documented here the evidence of the potential of the HPV vaccine to trigger a life-disabling autoimmune condition. The increasing number of similar reports of post HPV vaccine-linked autoimmunity and the uncertainty of long-term clinical benefits of HPV vaccination are a matter of public health that warrants further rigorous inquiry.
© 2013 John Wiley & Sons Ltd.
23902317 [PubMed – in process]
Full text: Blackwell Publishing
Lupus. 2012 Feb;21(2):223-30. doi: 10.1177/0961203311430221.
Human papillomavirus vaccine and systemic lupus erythematosus.
Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, Doria A, Shoenfeld Y.
Department of Medicine, University of Padova, Padova, Italy.
To investigate the association between human papillomavirus (HPV) vaccination and autoimmune manifestations compatible with systemic lupus erythematosus (SLE) or SLE-like disease, the medical history of six women who presented with SLE or SLE-like disease following HPV immunization was collected. Data regarding type of vaccine, number of immunization, family and personal, clinical and serological features, as well as response to treatments were analyzed. In the reported cases, several common features were observed, such as personal or familial susceptibility to autoimmunity or adverse response to a prior dose of the vaccine, both of which may be associated with a higher risk of post-vaccination autoimmunity. Favorable response to immunosuppressant was observed in all patients. In the current study, a temporal association between immunization with HPV vaccine and the appearance of a spectrum of SLE-like conditions is reported. Additionally, among the patients described, several common features were observed that may enable better identification of subjects at risk. Further studies are required to assess the safety of immunization with the HPV vaccine in patients with autoimmune-rheumatic diseases or in subject at risk of autoimmunity as well as the potential beneficial effect of preventive immunosuppressants.
[PubMed – in process]
Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations.
Tomljenovic L, Shaw CA.
Neural Dynamics Research Group, Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada. email@example.com
Immune challenges during early development, including those vaccine-induced, can lead to permanent detrimental alterations of the brain and immune function. Experimental evidence also shows that simultaneous administration of as little as two to three immune adjuvants can overcome genetic resistance to autoimmunity. In some developed countries, by the time children are 4 to 6 years old, they will have received a total of 126 antigenic compounds along with high amounts of aluminum (Al) adjuvants through routine vaccinations. According to the US Food and Drug Administration, safety assessments for vaccines have often not included appropriate toxicity studies because vaccines have not been viewed as inherently toxic. Taken together, these observations raise plausible concerns about the overall safety of current childhood vaccination programs. When assessing adjuvant toxicity in children, several key points ought to be considered: (i) infants and children should not be viewed as “small adults” with regard to toxicological risk as their unique physiology makes them much more vulnerable to toxic insults; (ii) in adult humans Al vaccine adjuvants have been linked to a variety of serious autoimmune and inflammatory conditions (i.e., “ASIA”), yet children are regularly exposed to much higher amounts of Al from vaccines than adults; (iii) it is often assumed that peripheral immune responses do not affect brain function. However, it is now clearly established that there is a bidirectional neuro-immune cross-talk that plays crucial roles in immunoregulation as well as brain function. In turn, perturbations of the neuro-immune axis have been demonstrated in many autoimmune diseases encompassed in “ASIA” and are thought to be driven by a hyperactive immune response; and (iv) the same components of the neuro-immune axis that play key roles in brain development and immune function are heavily targeted by Al adjuvants. In summary, research evidence shows that increasing concerns about current vaccination practices may indeed be warranted. Because children may be most at risk of vaccine-induced complications, a rigorous evaluation of the vaccine-related adverse health impacts in the pediatric population is urgently needed.
[PubMed – indexed for MEDLINE]
Am J Epidemiol. 2013 Aug 15;178(4):625-34. doi: 10.1093/aje/kwt018. Epub 2013 May 9.
Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination.
Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, Coutlée F, Villa LL, Franco EL.
Division of Cancer Epidemiology, Department of Oncology, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Currently, 2 vaccines exist that prevent infection by the genotypes of human papillomavirus (HPV) responsible for approximately 70% of cervical cancer cases worldwide. Although vaccination is expected to reduce the prevalence of these HPV types, there is concern about the effect this could have on the distribution of other oncogenic types. According to basic ecological principles, if competition exists between ≥2 different HPV types for niche occupation during natural infection, elimination of 1 type may lead to an increase in other type(s). Here, we discuss this issue of “type replacement” and present different epidemiologic approaches for evaluation of HPV type competition. Briefly, these approaches involve: 1) calculation of the expected frequency of coinfection under independence between HPV types for comparison with observed frequency; 2) construction of hierarchical logistic regression models for each vaccine-targeted type; and 3) construction of Kaplan-Meier curves and Cox models to evaluate sequential acquisition and clearance of HPV types according to baseline HPV status. We also discuss a related issue concerning diagnostic artifacts arising when multiple HPV types are present in specific samples (due to the inability of broad-spectrum assays to detect certain types present in lower concentrations). This may result in an apparent increase in previously undetected types postvaccination.
Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination
Deirdre Therese Little1,
Harvey Rodrick Grenville Ward2
+ Author Affiliations
Department of General Practice, North Bellingen Medical Services, Bellingen, Australia
Department of Obstetrics and Gynaecology, The University of New South Wales Rural Medical School in Coffs Harbour, Coffs Harbour, Australia
Correspondence to Dr Deirdre Therese Little, firstname.lastname@example.org
Premature ovarian failure in a well adolescent is a rare event. Its occurrence raises important questions about causation, which may signal other systemic concerns. This patient presented with amenorrhoea after identifying a change from her regular cycle to irregular and scant periods following vaccinations against human papillomavirus. She declined the oral contraceptives initially prescribed for amenorrhoea. The diagnostic tasks were to determine the reason for her secondary amenorrhoea and then to investigate for possible causes of the premature ovarian failure identified. Although the cause is unknown in 90% of cases, the remaining chief identifiable causes of this condition were excluded. Premature ovarian failure was then notified as a possible adverse event following this vaccination. The young woman was counselled regarding preservation of bone density, reproductive implications and relevant follow-up. This event could hold potential implications for population health and prompts further inquiry.
Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds?
Death after Quadrivalent Human Papillomavirus (HPV) Vaccination:Causal or Coincidental?
Report Concerning Survey of Adverse Events Following Inoculations with Gardasil
Japan withdraws support of controversial HPV vaccine over safety concerns
Health ministry withdraws recommendation for cervical cancer vaccine
A License to Kill? Part 1: How A Public-Private Partnership Made the Government Merck’s Gardasil Partner
The US Department of Health and Human Services recommends the vaccine for all teenagers, as if it is a disinterested third party, but does not disclose to families that it is a patent holder on the vaccine and receives a portion of the profits of every dose sold.
Press Conference on HPV Vaccines
Links and resources
Safe, Affordable, Necessary and Effective Vaccines and Vaccination Practices
The Truth about Gardasil
Gardasil and unexplained deaths – Emily Tarsell
One More Girl Movie
Canary Party Board Member Allison Chapman and Britt Fiste, seen is this video, are interviewed on Voice America’s “Holy Hormones Honey” show hosted by Leslie Carol Botha.
HPV Vaccine Injured Girls: I am Not a Coincidence